Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from SKAN Group AG ( (CH:SKAN) ) is now available.
SKAN Group AG reported a successful fiscal year 2024 with a significant increase in profits and strong order intake, driven by demand for advanced filling lines for oncology and obesity drugs. The company maintained its leadership in the isolator market and advanced its strategic initiatives for integrated process systems and standardization, while also enhancing its sustainability strategy. The company expects continued growth in 2025, despite potential revenue shifts in the first half of the year.
More about SKAN Group AG
SKAN Group AG operates in the pharmaceutical industry, focusing on providing process solutions for the aseptic filling of biopharmaceutical active ingredients. The company is known for its high-end isolator technology, catering to the growing demand for injectable drugs, particularly in oncology and obesity treatments.
YTD Price Performance: -5.91%
Average Trading Volume: 12,946
Current Market Cap: CHF1.62B
See more insights into SKAN stock on TipRanks’ Stock Analysis page.